Goldman Sachs Adds Fresenius Medical (FMS) to Pan-Europe Conviction Buy List

Goldman Sachs added Fresenius Medical Care (NYSE: FMS) to its Pan-Europe Conviction Buy List, saying the stock stock's 9% underperformance versus the sector since September 1st offers a compelling opportunity to buy a structural leader within EU Medtech.

Goldman revised its price target from EUR74 to EUR71 and lowered estimates 2%-3% to reflect weaker-than-expected 3Q12 results.

"We continue to view FMC as uniquely positioned to capitalize on the structural growth in the dialysis market given its dominant market position."

For an analyst ratings summary and ratings history on Fresenius Medical Care click here. For more ratings news on Fresenius Medical Care click here.

Shares of Fresenius Medical Care closed at $66.66 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
• New Street Research Upgrades Micron Technology (MU) to Buy